Research mapping and comparative assessment of drug treatment regimens for brucellosis: a systematic review and network meta-analysis

布鲁氏菌病药物治疗方案的研究现状及比较评价:系统评价和网络荟萃分析

阅读:2

Abstract

OBJECTIVE: There are different treatment regimens for treating human brucellosis. This study aimed to evaluate the comparative effectiveness and ranking of different treatment regimens for human brucellosis through a systematic review and network meta-analysis (NMA). METHODS: A systematic search was conducted in PubMed, ScienceDirect, Web of Science, and Embase to identify randomized controlled trials (RCTs) from their inception until February 1, 2023. Only RCTs comparing different treatment regimens for human brucellosis were included. The risk of bias was assessed using the Cochrane Risk of Bias tool. Consistency and heterogeneity were evaluated using Cochrane's I^2 and Q statistics. Our outcomes of interest include the "recovery" of patients with brucellosis following pharmacological treatment, as well as the "relative ranking" of the effectiveness of the studied treatment regimens compared to one another. Treatment effects were estimated using the relative risk (RR) effect size, while the P-score and Sucra was utilized to rank treatments in the NMA. A random-effects model was applied to account for between-study variability, and results were reported with 95% confidence intervals (CI). RESULTS: Out of 872 primary studies reviewed, a total of 32 studies were included in our network meta-analysis. The comparative effectiveness (measured by improvement) of the doxycycline (DOX) + streptomycin (SRT) + hydroxychloroquine (HYD) treatment regimen (RR:1.25, 95%CI: 1.07-1.45) is greater than other treatment regimens compared to DOX + rifampin (RIF) (RR:1) Following that, the DOX + STR + RIF and STR + ofloxacin (OFL) + RIF treatment regimens ranked second and third, respectively. The heterogeneity of the designs in our intervention network was estimated to be 37%, indicating low inconsistency within an acceptable range. CONCLUSION: The findings highlight the superior efficacy of triple-drug regimens, particularly those involving aminoglycosides, over dual-drug and monotherapy options. Our results confirm that DOX + STR + HYD is the most effective treatment regimens for human brucellosis. These new findings, when considering practical considerations, could inform the updating of clinical treatment protocols for human brucellosis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。